An Overview of the Treatment of Hematologic Malignancies
Julian Adams, PhD, from Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.
Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, discusses PI3K inhibitors and chemotherapies for the treatment of hematologic malignancies.
Traditionally, patients are treated with chemotherapy and anti-CD20 therapies. Eventually, Adams says, patients relapse and are no longer responsive. A further challenge arises in that many of these patients are elderly and cannot tolerate aggressive chemotherapies.
Clinical Pearls
Adams says that targeted therapies such as PI3K-delta and PI3K-gamma inhibitors will obviate the need for harsh therapies. With these therapies, physicians will be able to rescue patients from their chronic and aggressive diseases.
- Traditionally, a patient with a hematologic malignancy will be treated with chemotherapy and anti-CD20 therapies
- Many patients are elderly and cannot tolerate aggressive chemotherapies
- With targeted therapies like PI3K-delta and PI3K-gamma inhibitors, the need for harsh therapies will be obviated
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
